Eli Lilly › Financials
Ten years from Eli Lilly’s own SEC filings. Fiscal years end in December.
| Dec 2016fiscal year | Dec 2017fiscal year | Dec 2018fiscal year | Dec 2019fiscal year | Dec 2020fiscal year | Dec 2021fiscal year | Dec 2022fiscal year | Dec 2023fiscal year | Dec 2024fiscal year | Dec 2025fiscal year | Last 12 monthsto Jun 2026 | Latest quarterJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.22B | $19.97B | $21.49B | $22.32B | $24.54B | $28.32B | $28.54B | $34.12B | $45.04B | $65.18B | $79.67B | — |
| Net income | $2.74B | −$204.1M | $3.23B | $8.32B | $6.19B | $5.58B | $6.24B | $5.24B | $10.59B | $20.64B | $26.71B | — |
| Earnings per share, diluted | $2.58 | −$0.19 | $3.13 | $8.89 | $6.79 | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 | — | — |
| Dec 2016fiscal year | Dec 2017fiscal year | Dec 2018fiscal year | Dec 2019fiscal year | Dec 2020fiscal year | Dec 2021fiscal year | Dec 2022fiscal year | Dec 2023fiscal year | Dec 2024fiscal year | Dec 2025fiscal year | Last 12 monthsto Jun 2026 | Latest quarterJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.58B | $6.54B | $8.00B | $2.34B | $3.66B | $3.82B | $2.07B | $2.82B | $3.27B | $7.27B | — | $8.95B |
| Total assets | $38.81B | $44.98B | $43.91B | $39.29B | $46.63B | $48.81B | $49.49B | $64.01B | $78.71B | $112.48B | — | $142.28B |
| Debt | $9.01B | $13.65B | $12.77B | $13.64B | $16.35B | $16.74B | $14.82B | $19.10B | $29.47B | $42.50B | — | $54.91B |
| Total liabilities | $24.73B | $33.31B | $33.00B | $36.59B | $40.81B | $39.65B | $38.71B | $53.14B | $64.44B | $85.94B | — | $108.40B |
| Shareholders' equity | $14.01B | $11.59B | $9.83B | $2.61B | $5.64B | $8.98B | $10.65B | $10.77B | $14.19B | $26.54B | — | $33.88B |
| Dec 2016fiscal year | Dec 2017fiscal year | Dec 2018fiscal year | Dec 2019fiscal year | Dec 2020fiscal year | Dec 2021fiscal year | Dec 2022fiscal year | Dec 2023fiscal year | Dec 2024fiscal year | Dec 2025fiscal year | Last 12 monthsto Jun 2026 | Latest quarterJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.85B | $5.62B | $5.52B | $4.84B | $6.50B | $7.37B | $7.59B | $4.24B | $8.82B | $16.81B | $28.08B | — |
| Capital spending | $1.04B | $1.08B | $1.21B | $1.03B | $1.39B | $1.31B | $1.85B | $3.45B | $5.06B | $7.84B | $9.89B | — |
| Free cash flow | $3.81B | $4.54B | $4.31B | $3.80B | $5.11B | $6.06B | $5.73B | $792.0M | $3.76B | $8.97B | $18.19B | — |
| Buybacks | $600.1M | $299.8M | $4.15B | $4.40B | $500.0M | $1.25B | $1.50B | $750.0M | $2.50B | $4.11B | $6.17B | — |
| Dividends | $2.16B | $2.19B | $2.31B | $2.41B | $2.69B | $3.09B | $3.54B | $4.07B | $4.68B | $5.38B | $5.79B | — |
| Returned to shareholders | $2.76B | $2.49B | $6.46B | $6.81B | $3.19B | $4.34B | $5.04B | $4.82B | $7.18B | $9.49B | $11.96B | — |
| Stock-based pay | $255.3M | $281.3M | $279.5M | $312.4M | $308.1M | $342.8M | $371.1M | $629.0M | $646.0M | $626.0M | $649.0M | — |
Every column links to the filing it comes from on EDGAR. Last 12 months adds the latest year to date to the last 10-K and takes away the same months a year earlier. Debt is long-term debt including the part due within a year. A dash means the company did not report that line in a form we can read, never a zero. Market cap uses the latest closing price and the share count from the cover of the latest filing. How we count
$1,183.31B at $1,257.03 a share, with 941,357,065 shares outstanding as of Aug 3, 2026, from the cover of its latest SEC filing.
Revenue of $79.67B and net income of $26.71B in the last 12 months to Jun 2026.
Eli Lilly reported $54.91B of debt and $8.95B of cash and equivalents on its balance sheet in Jun 2026.
Yes. Operating cash flow minus capital spending was $18.19B in the last 12 months to Jun 2026.
$9.49B in buybacks and dividends in fiscal 2025, from the cash flow statement.
Free. Your email goes to Substack, which runs the newsletter. Privacy